Part I — The Science of Peptides

Chapters 1–6

You came here for a molecule. Probably a specific one. Semaglutide, because it is impossible to avoid hearing about. BPC-157, because someone at your gym is very confident about it. Copper peptides, because you own a bottle. Growth hormone, because a clinic sent you an email.

Part I is going to make you wait.

Not to be difficult, but because the fastest route to a real answer about any one peptide runs through six chapters that are mostly about something else. Here is why: almost every wrong belief about peptides is a failure of one of two skills — understanding what a molecule can physically do in a body, or understanding what a piece of evidence can legitimately prove. Get those two things, and the rest of the book becomes straightforward. Skip them, and you are collecting verdicts you cannot evaluate, which is exactly the situation you were in before you opened this book.

What the six chapters do

Chapter 1 — What Are Peptides? builds the molecule from nothing: twenty amino acids, one kind of bond, and the chain that results. By the end you can look at any compound and say whether it is a peptide, roughly how big it is, and where it sits between aspirin at 180 daltons and a therapeutic antibody at 148,000. You also learn why the peptide/protein line is a convention rather than a law — a small thing that turns out to matter every time somebody argues that "growth hormone isn't really a peptide."

Chapter 2 — How Peptides Work in Your Body is receptor biology. A peptide is a message; a receptor is what reads it. This chapter covers binding, signal transduction, the amplification that lets a picomolar hormone reorganize an organ, and the G-protein-coupled receptors that are the target of roughly a third of all approved drugs. It also introduces the discipline that recurs for the rest of the book: mechanism is necessary and never sufficient. Knowing how something would work is not evidence that it does.

Chapter 3 — The Endocrine System is the map. Hypothalamus to pituitary to gland to tissue; four axes; negative feedback; pulsatility. Every drug in Parts II through V acts somewhere on this map, and several of the field's most persistent confusions — why supplementing a hormone suppresses your own, why "raising growth hormone" is not the same as "getting the benefits of growth hormone" — resolve immediately once you can see it.

Chapter 4 — Peptide Pharmacology is the engineering problem. Peptides are exquisite signals and terrible drugs: destroyed by digestion, cleared in minutes, unable to cross most barriers. This chapter is about what it takes to fix that — and it introduces the book's central worked example, the three modifications that took GLP-1 from a two-minute half-life to a seven-day one. It also plants a question you will use constantly in Part III: if this molecule is so fragile, how exactly is the version being sold online supposed to survive contact with you?

Chapter 5 — How to Evaluate Peptide Evidence is the most important chapter in the book, and it contains almost no peptides. The evidence ladder. What an animal study can and cannot support. Trial phases. Blinding, randomization, endpoints, duration. Surrogate endpoints and the way they mislead. P-values, confidence intervals, hazard ratios, and number-needed-to-treat, in plain language. Relative versus absolute risk, worked in full. Estimands — why one honest trial reports two different weight-loss numbers. And then the four-tier rating system that the remaining thirty-five chapters run on.

Chapter 6 — The Peptide Hype Cycle explains the information environment you have been swimming in. It is a five-stage pipeline that runs from a real preclinical result to a sales page, and it is remarkably consistent across compounds. Once you have seen it drawn, you will recognize it in progress — including on compounds this book rates ✅, because good drugs get hyped too.

The thing Part I is really teaching

There is a sentence that appears in some form in every chapter of this book:

"It's a peptide" tells you almost nothing.

Insulin and BPC-157 are both peptides. One has kept people alive for a century; the other has never completed a randomized human trial. Semaglutide and melanotan II are both peptides. One has cardiovascular outcome data from a trial of roughly seventeen thousand people; the other is an unapproved tanning compound with a genuine melanoma concern.

The category is real — these molecules share a chemistry, a set of delivery problems, and a manufacturing story. But the category carries no evidentiary weight at all. Every peptide stands or falls on its own data, and Part I is where you acquire the equipment to read that data.

By Chapter 7, you will be ready to meet the drug that started all of this.

📋 Your Evidence Dossier — Part I

Part I opens the project. By the end of Chapter 6 you will have chosen your 5–10 peptides and filled in the first four fields for each — identity, origin, mechanism, and pharmacology — plus the two that matter most: Field 6, the rating, and Field 12, what would change your mind.

Field 12 is the one people skip. It is also the one that separates a considered position from a belief you happen to hold, and Chapter 6 explains why you should write it before you need it.

Chapters in This Part